Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also be monitored.


Clinical Trial Description

It is the intention of this protocol to study, in a controlled manner, the response of fingers of patients with Raynaud's phenomenon to two dosage strengths of a fast acting topical formulation of Nitroglycerin, MQX-503. Patients may have moderate to severe primary Raynaud's phenomenon or Raynaud's phenomenon secondary to autoimmune diseases such as scleroderma.

Quantitative changes in blood flow in the fingers of the non-dominant hand will be measured after the clinical induction of constriction of blood vessels by exposure to local cold temperatures. Secondarily, the quantitative reduction in skin temperature recovery time and symptoms of pain, tingling and numbness associated with Raynaud's phenomenon will be evaluated using a patient hand symptom analog assessment score. The frequency and severity of adverse events associated with MQX-503 will be assessed. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00480753
Study type Interventional
Source MediQuest Therapeutics
Contact
Status Completed
Phase Phase 2
Start date May 2007
Completion date August 2007

See also
  Status Clinical Trial Phase
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00048776 - Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Completed NCT00048763 - Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Enrolling by invitation NCT02615964 - Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. N/A
Completed NCT01309802 - A Two-Part Study of BOTOX® Therapy for Ischemic Digits Phase 2
Completed NCT02396238 - Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) N/A
Completed NCT00351117 - St. John's Wort in the Treatment of Raynaud's Phenomenon Phase 3
Completed NCT00528242 - Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Phase 2
Completed NCT00378521 - Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Phase 2
Completed NCT02683408 - Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon N/A
Active, not recruiting NCT00577304 - A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00419419 - Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00266669 - Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT01090492 - PF-00489791 For The Treatment Of Raynaud's Phase 2